Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases

Abstract

Background/AimMucolytic agents are often used in patients with COPD and bronchial asthma (BA) in Japan to decrease excessive mucus production, which is followed by improvement in dyspnea and QOL. However, the precise mechanism is unknown.Therefore, the actual mechanism of lysozyme hydrochloride (LYS), an oral anti-inflammatory enzyme preparation, in patients with COPD/BA was investigated.MethodThis study was a placebo-controlled, double-blind, randomized, cross-over design. Twenty-fourpatients with COPD and twenty-four patients with BA were enrolled.LYS or placebo was administered for 28 days in each treatment period, with a 28-day washout between the first and second treatment periods.The results ofimpulse oscillometry system (IOS) and spirometry examinations, as well as the changes in the symptoms ofsputum production, were evaluated after the treatment period.ResultsOn IOS examination, resistance of the respiratory system at 5 Hz (R5) levels was significantly improved only in patients with COPD (LYS vs placebo: -0.455 cm H₂O/L/s vs 0.095 cmH₂O/L/s, p =0.012). Similar trends were also found in R20, X5, and AX. On spirometry, airway function (FEV1)improved in patients with COPD after administration of LYS (LYS vs placebo: 0.062 L vs 0.025 L, p = 0.062). Similar trends were also found in %FEV1 in COPD patients. Subjective symptoms of sputum production also tended to improve only during the LYS treatment period. No adversereactions were observed during the study.ConclusionLYS, a mucolytic agent, may improve the function of peripheral airways, which is followed by improvement in the patients' symptoms and QOL.

Rating:

Share or cite this content

Citations should be made in the following way:
H. Ohbayashi, Y. Setoguchi, Y. Fukuchi, K. Shibata, Y. Sakata, T. Arai (Mizunami, Shinjuku, Bunkyo, Japan). Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study. Eur Respir J 2014; 44: Suppl. 58, 1502

Member's Comments

No comment yet.

Related content which might interest you: The effect of Theophylline in patients with allergic rhinitis: A double-blind, randomised, crossover study Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013 A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Comparison of an innovative multi-dose inhaler with the attributes of an 'ideal' inhaler: A multicentre randomised controlled trial (RCT) Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Aerobic training decreases bronchial hyperresponsiveness, serum chemokines and symptoms in asthmatic patients: Randomized controlled trial Source: Annual Congress 2013 –Rehabilitation, exercise and adjunct physiotherapy techniques in different respiratory conditions Year: 2013 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012